ArticleKidney3602026
Effects of Atrasentan on Kidney Gene Transcription, Mesangial Cell Proliferation, and Proteinuria in IgA Nephropathy.
Article in Kidney360, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and Safety of Atrasentan in Patients with IgA Nephropathy Receiving Sodium-Glucose Cotransporter 2 Inhibitors: Placebo-Controlled, Crossover Trial.Journal of the American Society of Nephrology : JASN · 2026Trial
- The Alternative Complement Pathway in IgA Nephropathy: A Podcast for Advanced Practice Providers.Advances in therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
key pointsIn human renal mesangial cells stimulated with endothelin-1, atrasentan reduced mesangial cell proliferation and matrix expansion. Atrasentan reduced kidney injury in two preclinical models of IgA nephropathy. These findings support the therapeutic potential of atrasentan to treat IgA nephropathy; clinical studies of atrasentan are ongoing.
backgroundIgA nephropathy (IgAN) is the leading cause of primary GN and carries a high risk of progression to ESKD. Endothelin-1 type A (ET A ) receptor activation may be a key driver of proteinuria, inflammation, and fibrosis in patients with kidney diseases. Atrasentan, a highly potent and highly selective antagonist of the ET A receptor, demonstrated a statistically significant and clinically meaningful proteinuria reduction of 36.1% (95% confidence interval, 26.4% to 44.6%; P < 0.001) relative to placebo, at week 36 in the ongoing Atrasentan in Patients With IgA Nephropathy (ALIGN) phase 3 trial. Based on these data, atrasentan is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.
methodsWe explored the biologic effects and changes in gene transcription with atrasentan in cultured human renal mesangial cells, grouped ddY mouse model of IgAN, and Wistar rats injected with anti-Thy1.1 (CD90) antibody to induce mesangial injury and mesangioproliferative GN. The effect of atrasentan on proteinuria and kidney gene transcriptome was evaluated in both animal models, and histologic and morphometric assessments of rat kidneys were conducted.
resultsIn separate transcriptomics analyses of all three models, atrasentan reversed gene expression changes related to cell proliferation, proinflammatory, and profibrotic signatures. In human renal mesangial cells stimulated with endothelin-1, atrasentan reduced mesangial cell proliferation and matrix expansion. After 7 days, atrasentan treatment in the mesangioproliferative GN rat model diminished renal mesangial hypercellularity and matrix expansion, decreased glomerular and tubulointerstitial structural alterations, and significantly reduced proteinuria. In grouped ddY mice, atrasentan treatment for 4 days significantly reduced mean albuminuria by >60%.
conclusionsThe acute mechanistic effects of atrasentan demonstrated in vitro and in vivo support the therapeutic potential of atrasentan in IgAN. The ongoing Atrasentan in Patients With Proteinuric Glomerular Diseases (AFFINITY) and Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy (ASSIST) phase 2 trials, and the ALIGN phase 3 trial in patients with IgAN will further evaluate the translation of these mechanistic effects to the clinical efficacy and safety of atrasentan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.